Diebold Nixdorf, Incorporated
DBD · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,751 | $3,761 | $3,461 | $3,905 |
| % Growth | -0.2% | 8.7% | -11.4% | – |
| Cost of Goods Sold | $2,831 | $2,884 | $2,703 | $2,862 |
| Gross Profit | $920 | $876 | $757 | $1,043 |
| % Margin | 24.5% | 23.3% | 21.9% | 26.7% |
| R&D Expenses | $94 | $111 | $121 | $126 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $644 | $0 | $742 | $776 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $678 | $107 | $4 |
| Operating Expenses | $738 | $789 | $969 | $906 |
| Operating Income | $182 | $87 | -$212 | $137 |
| % Margin | 4.9% | 2.3% | -6.1% | 3.5% |
| Other Income/Exp. Net | -$132 | $1,365 | -$225 | -$188 |
| Pre-Tax Income | $50 | $1,452 | -$436 | -$50 |
| Tax Expense | $64 | $76 | $149 | $28 |
| Net Income | -$17 | $1,376 | -$581 | -$79 |
| % Margin | -0.4% | 36.6% | -16.8% | -2% |
| EPS | -0.44 | 21.38 | -7.44 | -1 |
| % Growth | -102.1% | 387.4% | -644% | – |
| EPS Diluted | -0.44 | 21.38 | -7.44 | -1 |
| Weighted Avg Shares Out | 38 | 64 | 79 | 78 |
| Weighted Avg Shares Out Dil | 38 | 64 | 79 | 78 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12 | $13 | $10 | $6 |
| Interest Expense | $155 | $246 | $199 | $195 |
| Depreciation & Amortization | $132 | $126 | $126 | $149 |
| EBITDA | $335 | $275 | -$113 | $294 |
| % Margin | 8.9% | 7.3% | -3.3% | 7.5% |